Two previously conducted clinical studies assessed lost nonworkplace activity time and lost workplace productivity time due to migraine symptoms in subjects using sumatriptan for 6 months to treat their migraines after a 12-to 18-week period of using their usual therapy without sumatriptan.
Although statistically significant differences in lost nonworkplace activity time and lost workplace productivity time between the usual therapy and sumatriptan treatment periods were detected using the Wilcoxon signed-rank test, this test could not determine whether differences were attributable to inherent trends in the data.
This current study employed time series analysis, which detects and controls for preexisting trends in data, to further explore the possibility that the observed reductions in lost time in the two clinical studies were related to management of the subjects with sumatriptan.
The intercepts and slopes of the computed linear models suggest that the initiation of sumatriptan therapy produced savings of 0.8 hours of nonworkplace activity time and 0.5 hours of workplace productivity time per patient per week.
These savings were sustained throughout the sumatriptan treatment period.
Preexisting trends in the data were not detected in the models. (...)
Mots-clés Pascal : Sumatriptan, Antimigraineux, Chimiothérapie, Migraine, Traitement, Productivité travail, Absentéisme, Homme, Etats Unis, Amérique du Nord, Amérique, Douleur, Système nerveux pathologie, Système nerveux central pathologie, Encéphale pathologie, Cérébrovasculaire pathologie, Appareil circulatoire pathologie, Vaisseau sanguin pathologie
Mots-clés Pascal anglais : Sumatriptan, Antimigrainous agent, Chemotherapy, Migraine, Treatment, Labour productivity, Absenteeism, Human, United States, North America, America, Pain, Nervous system diseases, Central nervous system disease, Cerebral disorder, Cerebrovascular disease, Cardiovascular disease, Vascular disease
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 97-0155936
Code Inist : 002B02F04. Création : 21/05/1997.